EGFR酪氨酸激酶区域基因变异与吉非替尼治疗非小细胞肺癌临床因素相关性研究进展

被引:3
作者
赵向飞
刘晓晴
机构
[1] 军事医学科学院附属医院肿瘤一科
关键词
EGFR突变; 非小细胞肺癌; 吉非替尼;
D O I
暂无
中图分类号
R734.2 [肺肿瘤];
学科分类号
100214 ;
摘要
吉非替尼是表皮性生长因子受体(EGFR)酪氨酸激酶抑制剂,在非小细胞肺癌的治疗中受到普遍关注,而EGFR突变有助于筛选针对吉非替尼治疗的受益人群,本文回顾了近期国外对EGFR突变及其与病理类型、种族、性别、生存期等临床因素的相关性。
引用
收藏
页码:1438 / 1441
页数:4
相关论文
共 35 条
[21]  
Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Hideharu Kimura,Kazuo Kasahara,Makoto Kawaishi,et al. Clinical Cancer Research . 2006
[22]  
The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. Zhang XT,Li LY,Mu XL,et al. Annals of Oncology . 2005
[23]  
Epidermal growth factor receptor gene mutation defines distinct subsets among small adenocarcinomas of the lung. Hiroshi Haneda Hidefumi Sasaki Shigeki Shimizu Katsuhiko Endo Eriko Suzuki Haruhiro Yukiue Yoshihiro Kobayashi Motoki Yanoa. Lung Cancer . 2006
[24]  
A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma. Haneda H,Sasaki H,Lindeman N, et al. Japanese Journal of Clinical Oncology . 2006
[25]  
Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. Tsao AS,Tang XM,Sabloff B,Xiao L,Shigematsu H,Roth J,Spitz M,Hong WK,Gazdar A,Wistuba I. J Thorac Oncol . 2006
[26]  
Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery. Kondo M,Yokoyama T,Fukui T,Yoshioka H,Yokoi K,Nagasaka T,Imaizumi K,Kume H,Hasegawa Y,Shimokata K et al. Lung Cancer . 2005
[27]  
The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Tokumo M,Toyooka S,Kiura K, et al. Clin Cancer Res . 2005
[28]  
Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. Lynch TJ,Bell DW,Sordella R,et al. The New England Journal of Medicine . 2004
[29]  
Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with non small cell lung cancer. Sone T,Kasahara K,Kimura H,et al. Cancer . 2007
[30]  
Epi-dermal growth factor receptor messenger RNA expression,gene dosage,and Gefitinib sensitivity in non-small cell lung cancer. Rafal Dziadziuszko,Samir E Witta,Federico Cappuzzo,et al. Clinical Cancer Research . 2006